EMA Authorised: Ontozry (cenobamate) — Angelini Pharma S.p.A

View source ↗

Summary

The EMA has authorised Ontozry (cenobamate) from Angelini Pharma S.p.A. for epilepsy in the European Union, with decision dated 17 November 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Ontozry (cenobamate)

Snippet

Status: Authorised. Therapeutic area: Epilepsy. MAH: Angelini Pharma S.p.A. Decision date: 17/11/2025